Pioneer-backed NuVision raises £4.8 million to expand internationally
Bitget2026/10/22 12:07- NuVision Biotherapies raised £4.8 million in a Mercia Ventures-led round involving Pioneer Group to expand internationally and scale operations.
- Freenome debuted on Nasdaq in July 2026; its SimpleScreen CRC blood-based colorectal cancer screening program secured FDA approval in late July.
- The FDA granted Freenome’s SimpleScreen lung cancer screening test Breakthrough Device Designation in August 2026.
- 4D Medicine is finalizing its Series A; Inaphaea BioLabs’ drug evaluation prompted ValiRx to negotiate an exclusive license and fund preclinical development.
- SurePulse Medical’s wireless monitor demonstrated feasibility in preterm infants; Locate Bio’s peer-reviewed study supported LDGraft’s evidence base for bone regeneration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Positive outlook hinges on 1.1280 against US Dollar - UOB
USD/JPY Price Forecast: Remains close to 20-day EMA
OpenAI president confirms IPO in 2027: enterprise clients have become the main source of revenue, but funding target has shrunk from 30 billions to 20 billions
OpenAI President Brockman stated that enterprise sales have contributed the majority of the company's revenue, and the company will be ready for an IPO by 2027. OpenAI is accelerating fundraising and competing with Anthropic, which is aiming to go public by the end of the year.
Former Citi executive Klein establishes another SPAC; Churchill Capital XIV (CXIVU.US) plans to raise up to $300 million in US IPO
Churchill Capital XIV filed an application with the SEC on Wednesday, seeking to raise up to $300 million through an initial public offering (IPO).
Crypto prices
More
